$6.34-0.11 (-1.71%)
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases.
Anteris Technologies Global Corp. in the Healthcare sector is trading at $6.34 with a market capitalization of $618M. Wall Street consensus targets $13.57 (5 analysts), implying a +114.1% move over the next 12 months. The stock is currently 43% below its 52-week high of $11.05, remaining 13.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.01Mβ | $494,000β | $310,000β | $429,000β | $618,000 |
| Gross Profit | $776,000β | $380,000β | $219,000β | $306,000β | $470,000 |
| Operating Income | -$31.00Mβ | -$24.01Mβ | -$29.21Mβ | -$22.27Mβ | -$20.88M |
| Net Income | -$29.09Mβ | -$23.02Mβ | -$29.20Mβ | -$22.24Mβ | -$20.83M |
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for...